EFFECTS OF MYRICETIN ON THE PREVENTION OF SEPSIS-RELATED TISSUE INJURY

Myricetin, a flavonoid, is being investigated for its potential use in the treatment of various diseases due to its anti-inflammatory, antioxidant, and anticancer effects, with extensive research ongoing in this area. Sepsis is an infectious disease and is a clinical condition with high mortality and morbidity due to the damage it causes to organ and tissue systems. Studies on sepsis and myricetin focus on whether myricetin prevents organ and tissue damage that occurs during sepsis and the mechanisms by which it does this. When satisfactory results are obtained from these studies, myricetin can be used as an agent to reduce and prevent organ and tissue damage in the treatment of sepsis, resulting in a significant decrease in mortality and morbidity in patients with sepsis. Sepsis causes damage to the respiratory, cardiovascular, renal, hematological, gastrointestinal, and central nervous systems. There are many mechanisms in the formation of these damages. These include excessive production of cytokines such as TNF-alpha, IL-1 alpha, IL-6, and IL-8 due to an excessive inflammatory response, resulting in a condition called a cytokine storm; secretion of myeloperoxidase (MPO), elastase, and free radicals by neutrophils migrating into the tissue, resulting in excessive activation of neutrophils; excessive activity of iNOS/NO, hypotension, and increased vascular permeability, leading to endothelial dysfunction and vasoplegia; disruption of the Bax/Bcl-2 balance and mitochondrial dysfunction due to Caspase-1 activation, and cell death by apoptosis. In this section of our book, we will explain the organ damage that occurs in sepsis, the mechanisms of this organ damage, the protective effects of myricetin against organ damage, the possible clinical implications, and recommendations for the future in detail.